No Data
No Data
Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Buy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer Treatment
Express News | Compass Therapeutics Completes Patient Enrollment in Companion-002, a Randomized Study of Ctx-009 in Combination With Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Recent 32% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
No Data